Neurocrine Biosciences (NBIX) Capital Expenditures Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 28.56% |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 279.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.64% |
| Dec 31, 2025 | 44.45% |
| Sep 30, 2025 | 35.72% |
| Jun 30, 2025 | -66.69% |
| Mar 31, 2025 | 56.34% |
| Dec 31, 2024 | 61.37% |
| Sep 30, 2024 | -30.12% |
| Jun 30, 2024 | -79.28% |
| Mar 31, 2024 | 382.03% |
| Dec 31, 2023 | -45.34% |
| Sep 30, 2023 | -20.63% |
| Jun 30, 2023 | 25.99% |
| Mar 31, 2023 | -9.14% |
| Dec 31, 2022 | -8.70% |
| Sep 30, 2022 | 7.85% |
| Jun 30, 2022 | -102.74% |
| Mar 31, 2022 | 67.11% |
| Dec 31, 2021 | -27.13% |
| Sep 30, 2021 | 66.91% |
| Jun 30, 2021 | -31.18% |